Based in Sydney, Australia, Immutep Limited is a clinical-stage biotechnology company focused on developing immunotherapies targeting Lymphocyte Activation Gene-3 (LAG-3), an immune checkpoint mechanism. The company's lead candidate is eftilagimod alfa (efti or IMP321), a soluble LAG-3 fusion protein designed to enhance immune response against cancer. Immutep is advancing multiple programs across oncology and autoimmune diseases through partnerships with major pharmaceutical firms including Merck & Co., Novartis, and EOC Pharma.
The company's oncology pipeline includes several phase II and phase III candidates in development. TACTI-004 is in phase III trials for first-line non-small cell lung cancer, while TACTI-003 is in phase IIb for head and neck squamous cell carcinoma. Additional programs address metastatic urothelial carcinoma (INSIGHT-005), soft tissue sarcoma (EFTISARC-NEO), and metastatic breast cancer (AIPAC-003). Immutep also maintains early-stage programs in autoimmune disease, including IMP761 in phase I development.
Immutep was incorporated in 1987 and operates as an Australian public company listed on Nasdaq. The company generates revenue primarily through research and development activities and partnership arrangements rather than product sales, reflecting its pre-commercial stage of development.
No 10-K filings found.